Trial Profile

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 23 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GT 801 (Primary)
Indications B-cell lymphoma; Haematological malignancies; Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; First in man
Sponsors GRIT Biotechnology

06 Dec 2025 According to a Vivacta Bio media release, as of the November 30, 2025 data cutoff, two patients with non-Hodgkin's lymphoma have received multiple administrations of GT801 in the ongoing trial without lymphodepleting chemotherapy.
06 Dec 2025 Results presented in a Vivacta Bio media release
06 Dec 2025 According to a Vivacta Bio media release, initial data from the trial were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com